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Abstract. – The COVID-19 pandemic de-
mands a reassessment of head and neck on-
cology treatment paradigms by posing several 
challenges for oncology services, with unprece-
dented pressure on the regional health care sys-
tem. Since February 2020 this has severely dis-
rupted health-care services, leading to accumu-
lating clinic caseload and substantial delays for 
operations. The head and neck cancer services 
have been faced with the difficult task of manag-
ing the balance between infection risk to health-
care providers and the risk of disease progres-
sion from prolonged waiting times. Herein, we 
share our experience in Firenze (Italy) and pro-
pose our action plan on the management of 
head and neck cancer services via multi-institu-
tion collaboration.
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In Italy, since February 2020, hospital admis-
sions, clinic attendances and medical resources 
have been significantly diverted to tackle the 
Coronavirus disease-19 (COVID-19)-pandemic 
with a subsequent reassessment of head and 
neck cancer patients management1. COVID-19 
has delayed all the screening and follow-up 
programs and, by looking at the immediate 
post-lockdown oncology service admissions, 
we are confronted with the question as whether 
the risk-benefit ratio was to a large extent neg-
atively affected. Are we going to face a greater 
number of advanced, less curable cases in the 
upcoming months? 
The COVID-19 pandemic has demanded re-
assessment of head and neck oncology treat-
ment paradigms by posing several challenges 
for oncology services and it is undoubted that 
the National Health System has been under 
unprecedented pressure during the last three 
months2. In this regard, the European Society 
of Surgical Oncology (ESSO) advised against 
seeing patients older than 70 years in the clin-
ic, unless urgent3; the Governor of Tuscany 
itself, has issued ordinances reporting advises 
and guidelines emphasizing the importance 
of recognizing patients’ urgency priorities by 
preserving the workforce from burn-out. On 
the other hand, these measures have postponed 
non-urgent appointments, whose evaluations 
were entrusted to general practitioners and 
not to head and neck specialists, and efforts 
to relocate cancer teams and services away 
from general hospitals caring for patients with 
COVID-19 were not undertaken. These con-
ditions, added to travel restrictions and wide-
spread apprehension, generated a significant 
reduction in investigations for new cancer di-
agnoses and cancer surgery, which drastically 
decreased crucial insights to undertake cancer 
patients’ decision-making. Lastly, the effects of 
COVID-19 are not solely limited to the treat-
ment of patients with cancer, but will also hit 
the wider oncology community, with inevitable 
consequences for research, education, and col-
laboration4.
To confront the challenge of limited resourc-
es and reduced operating lists, Italian head and 
neck centers stratified operations according 
to the aggressiveness of the tumor, potential 
effect on reconstruction, and anticipated com-
plications5. In this setting, it does merit brief 
acknowledgment that the effect of a reasonable 
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delay in the management of particular low-risk 
malignancies (i.e. skin cancers or low grade 
salivary malignancies) will only marginally af-
fect the quantity and quality of life. Converse-
ly, the treatment for potentially curable cancers 
with a concrete risk of becoming not resectable 
or not eligible for treatment with curable intent 
cannot be safely postponed6.
In order to avoid serious ethical issues and 
preserve the highest standards of care and 
treatment for patients, head and neck cancer 
multidisciplinary team remained the best strat-
egy to opt for balanced and appropriate treat-
ments our patients deserve, without affecting 
their quantity and quality of life. From our 
preliminary analysis insights, we observed a 
three-fold increase in advanced cancer stages 
diagnoses between April and May 2020 when 
compared with the same period of the last year 
(63.5% vs. 21.8%). Interestingly, non-surgical 
treatment indications almost doubled for same 
stage cases (21.2% vs. 16.6%).
Online consultation/telehealth has been 
strongly recommended by oncology organi-
zations, including the European Society for 
Medical Oncology, but it represents a huge 
change in how staff interact with patients and 
it is not always suitable for each patient either 
oncology specialists7. It has been predicted that 
new ways of working in cancer care during the 
COVID-19 pandemic will permanently change 
oncology services, after evaluating their im-
pact8.
In our opinion, action plan should include 
multilevel risks stratifications, strengthen 
safety measures and diagnostic facilities to 
face the increase in workload, complexity of 
the disease, overlapping problems including 
COVID-19 potential new infections. Head and 
Neck regional cancer HUBs should be encour-
aged to provide outpatients assessment, includ-
ing all of the safety measures and diagnostic 
facilities; one-day staging and pre-hospitaliza-
tion schedule, to allow the multidisciplinary 
tutor board group to express treatment indica-
tions in one setting without requiring one week 
more to complete the staging process. Further-
more, in the post-lockdown phase, we need to 
avoid backlashes even on social and economic 
aspects, by eliminating misconcenptions9. 
Now, we need to promote patients’ safety, 
treatment, and compliance, and ameliorating 
patients’ stress. This awareness should be guid-
ed by social-media and policymakers, because 
once the fear of COVID-19 will diminish, 
problems related to diagnostic and treatment 
withdrawal will remain10.
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